Merck & Co., Inc. (NYSE:MRK) Position Boosted by Chicago Partners Investment Group LLC

by · The Cerbat Gem

Chicago Partners Investment Group LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,294 shares of the company’s stock after acquiring an additional 289 shares during the period. Chicago Partners Investment Group LLC’s holdings in Merck & Co., Inc. were worth $2,478,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at about $39,000. Abich Financial Wealth Management LLC increased its stake in Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. Quarry LP acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $42,000. Strategic Financial Concepts LLC boosted its holdings in shares of Merck & Co., Inc. by 1,475.6% in the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after acquiring an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 47.5% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after acquiring an additional 122 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $101.88 on Friday. The firm has a market cap of $258.04 billion, a price-to-earnings ratio of 21.36, a P/E/G ratio of 1.46 and a beta of 0.40. Merck & Co., Inc. has a 1 year low of $98.60 and a 1 year high of $134.63. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80. The business has a fifty day simple moving average of $112.29 and a 200 day simple moving average of $120.84.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $2.13 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MRK shares. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. Bank of America cut their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. BMO Capital Markets lowered their target price on Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating on the stock in a report on Friday. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $129.93.

Read Our Latest Research Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).